Tuesday, June 25, 2019

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI) Continues to Transform Cannabis Landscape with Novel Products, Technology


  • A partnership with PAX will allow Organigram to manufacture and fill pods for the premium, technology-based PAX Era vaporizer
  • The PAX partnership is expected to enable the two entities to seize new opportunities on the market and work together to develop premium products featuring disruptive, industry-leading technology that is set to redefine the experience of vaping
  • An agreement signed with Feather Company Ltd. makes Organigram the exclusive Canadian supplier of unique and proprietary vaporizer pen technology
  • Organigram is selling to all 10 Canadian provinces
  • The company is on track to increase production capacity and is well positioned for Canada’s new edibles and derivative legislation, slated for October 2019
Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI), a leading Canadian licensed producer (LP) of high-quality cannabis and extract-based products, continues to develop exclusive partnerships and introduce innovative products that enhance the cannabis lifestyle for its customers. An exclusive agreement signed with Feather Company Ltd. illustrates this laser focus on customer experience as Organigram looks forward to Canada’s legalization of new cannabis product categories, as the company stated in a news release (http://ibn.fm/T4kfV).

“A successful recreational cannabis market requires that licensed producers and their partners continually reimagine the cannabis experience,” Ray Gracewood, senior vice president, marketing and communications for Organigram, stated in the release. “It is critical for Organigram to find unique ways to offer customers the kind of value that will help differentiate our brands. The future is in providing unique opportunities for customers to explore the product.”

The exclusive agreement between Organigram and Feather, a cannabis innovator and lifestyle brand committed to the production of premium-quality products, creates a mutually beneficial relationship for the two companies. Organigram, through its Edison Cannabis Co. brand, will hold an exclusive license to Feather’s proprietary vaporizer pen technology and form factor. Organigram will also represent Feather across Canada from a commercial perspective and plans to approach all 10 provinces with Feather’s disposable and cartridge-based units.

“We are thrilled to be working with Organigram,” Feather CEO Patrick Lehoux stated in the release. “As patients, enthusiasts and advocates for the cannabis community, we are committed to applying our diverse skills to produce the best experience for consumers. Our partnership with Organigram opens new and exciting opportunities for us to do just that. We believe in the Edison brand and Organigram’s best-in-class facility ensures that we are partnered with a team committed to producing a consistent, premium product.”

The disposable vaporizer pen and 5/10 thread cartridges for targeted adult-use customer segments are expected to be available as this product category becomes legal in Canada by mid-October 2019. Feather’s technology and hardware offers Organigram’s Edison brand a unique, proprietary delivery mechanism for discerning and sophisticated consumers and will complement the company’s partnership with PAX, a leader in closed-loop vaporizable technology offered through the PAX Era product line  (http://ibn.fm/lXIpJ).

Organigram is planning on working with and offering the Edison Cannabis Co.-branded PAX Era pods to all 10 of its provincial partners to achieve coast-to-coast distribution. The pods will be filled onsite at Organigram’s Moncton facility at the company’s phase 5 refurbishment.

As concentrates are anticipated to become legal in Canada later in 2019, giving birth to a wide range of new market development opportunities, strategic partnerships like the one between Organigram and PAX Labs are expected to allow the immediate launch of premium products featuring a disruptive, industry-leading technology that is set to redefine the experience of vaping.

“Cannabis 2.0 – the next generation of legal, adult use cannabis products – represents a world of opportunity,” Organigram CEO Greg Engel added. “Innovative partnerships with exceptional companies like PAX mean our own product offering grows and our customers have access to cutting-edge technology and cannabis experiences.”

The agreement with PAX reflects Organigram’s strategic commitment to growth and leadership through technology-driven innovation. Additionally, the company has been building up significant levels of concentrate in anticipation of the Canadian legislative change and the launch of Cannabis 2.0 vape pens and edibles later in 2019. According to Engel, this is just the beginning for his company, whose team is strongly committed to developing exceptional and imaginative products that support both the organization’s business objectives and its customers’ needs.

Further cementing its position, Organigram earlier in 2019 secured distribution agreements in all 10 Canadian provinces, becoming one of just three licensed producers in Canada to do so (http://ibn.fm/NCowK). The company boasts the lowest cost of cultivation among Canadian licensed producers, driven by industry-leading yields.

For more information, visit the company’s website at www.Organigram.ca

NOTE TO INVESTORS: The latest news and updates relating to OGI are available in the company’s newsroom at http://ibn.fm/OGRMF

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html